NCT03299946View on ClinicalTrials.gov

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

December 9, 2019

Study Completion Date

October 1, 2021

Conditions
Locally Advanced Hepatocellular Carcinoma
Interventions
DRUG

Cabozantinib

Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.

DRUG

Nivolumab

Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03299946 - Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter